Lee was most recently Senior Director and Distinguished Scientist in Translational Medicine at Genentech, leading a group responsible for biomarker development for programs in neuroscience, ophthalmology, cardiovascular and metabolic disease.
He is author on >20 publications related to biomarkers for Alzheimer’s disease and neurodegeneration from his work at Genentech. Prior to Genentech, Lee was at Pharmacyclics and led the preclinical development of the btk inhibitor ibrutinib, including use of a novel target engagement biomarker in Phase I. Ibrutinib was the first approved Btk inhibitor, establishing a new standard of treatment in chronic lymphocytic leukemia (CLL). Lee’s contributions were recognized by the 2019 ACS Heroes in Chemistry award. Lee also worked at Celera Genomics where he used genetics and model organisms for target discovery and lead optimization.
Lee received a PhD in Neuroscience from UCSF and a BA in Computer Science from Dartmouth College.